A detailed history of Farther Finance Advisors, LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Farther Finance Advisors, LLC holds 57 shares of BPMC stock, worth $5,130. This represents 0.0% of its overall portfolio holdings.

Number of Shares
57
Previous 29 96.55%
Holding current value
$5,130
Previous $2.8 Million 122.57%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
$85.18 - $108.78 $2,385 - $3,045
28 Added 96.55%
57 $6.22 Million
Q1 2024

May 13, 2024

BUY
$73.17 - $99.79 $1,682 - $2,295
23 Added 383.33%
29 $2.8 Million
Q4 2023

Feb 14, 2024

BUY
$43.96 - $92.84 $791 - $1,671
18 Added 300.0%
24 $2.21 Million
Q1 2023

May 13, 2024

SELL
$37.97 - $50.0 $683 - $900
-18 Reduced 75.0%
6 $270,000
Q1 2023

Sep 12, 2023

BUY
$37.97 - $50.0 $113 - $150
3 Added 100.0%
6 $270,000
Q4 2022

Sep 11, 2023

BUY
$41.06 - $66.48 $123 - $199
3 New
3 $131,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.37B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Farther Finance Advisors, LLC Portfolio

Follow Farther Finance Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Farther Finance Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farther Finance Advisors, LLC with notifications on news.